More articles from psychopharmacology for the clinician

Open Access
Serotonin syndrome: SSRIs are not the only culprit
Nicolas Garel, Kyle T. Greenway, Karim Tabbane and Ridha Joober

J Psychiatry Neurosci May 01, 2021 46 (3) E369-E370; DOI: https://doi.org/10.1503/jpn.210001
Open Access
Binge eating disorder hidden behind a wall of anxiety disorders
Amy Pipe, Beth Patterson and Michael Van Ameringen

J Psychiatry Neurosci March 01, 2021 46 (2) E208-E209; DOI: https://doi.org/10.1503/jpn200235
Open Access
Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination
Deborah Thompson, Clay M. Delorme, Randall F. White and William G. Honer

J Psychiatry Neurosci March 01, 2021 46 (2) E210-E211; DOI: https://doi.org/10.1503/jpn.210027
Open Access
The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder
Nicolas Garel, Kyle T. Greenway and Ridha Joober

J Psychiatry Neurosci January 01, 2021 46 (1) E164-E165; DOI: https://doi.org/10.1503/jpn.200114
You have access
Therapeutic abstention in the treatment of depression in first-episode psychosis
Priyadharshini Sabesan and Lena Palaniyappan

J Psychiatry Neurosci November 01, 2020 45 (6) 441-442; DOI: https://doi.org/10.1503/jpn.200059
You have access
Treating anxious syndromes with pregabalin in patients with psychosis
Nicolas Garel, David Bloom and Ridha Joober

J Psychiatry Neurosci September 01, 2020 45 (5) 370; DOI: https://doi.org/10.1503/jpn.200033
You have access
Long-acting injectable antipsychotics: choosing the right dose
David Carlone and Nicholas Delva

J Psychiatry Neurosci July 01, 2020 45 (4) 298; DOI: https://doi.org/10.1503/jpn.200015
You have access
Consensus statement on the use of clozapine during the COVID-19 pandemic
Dan Siskind, William G. Honer, Scott Clark, Christoph U. Correll, Alkomiet Hasan, Oliver Howes, John M. Kane, Deanna L. Kelly, Robert Laitman, Jimmy Lee, James H. MacCabe, Nick Myles, Jimmi Nielsen, Peter F. Schulte, David Taylor, Helene Verdoux, Amanda Wheeler and Oliver Freudenreich

J Psychiatry Neurosci May 01, 2020 45 (3) 222-223; DOI: https://doi.org/10.1503/jpn.200061
You have access
Mu-opioid antagonism in the treatment of cannabis use disorder
Oussama Kebir, Xavier Laqueille and Fayçal Mouaffak

J Psychiatry Neurosci March 01, 2020 45 (2) 143-144; DOI: https://doi.org/10.1503/jpn.190182
You have access
Kleptomania treated with naltrexone in a patient with intellectual disability
Faycal Mouaffak, Sonia Hamzaoui, Oussama Kebir and Xavier Laqueille

J Psychiatry Neurosci January 01, 2020 45 (1) 71-72; DOI: https://doi.org/10.1503/jpn.190064

Main menu

User menu

Search

More articles from psychopharmacology for the clinician

Pages

Content

Authors & Reviewers

About